Daily Stock Analysis, KPTI, Karyopharm Therapeutics Inc, priceseries

Karyopharm Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
17.85
Close
18.09
High
18.69
Low
17.70
Previous Close
18.06
Daily Price Gain
0.03
YTD High
29.61
YTD High Date
Mar 2, 2020
YTD Low
13.39
YTD Low Date
Feb 27, 2020
YTD Price Change
-0.63
YTD Gain
-3.37%
52 Week High
29.61
52 Week High Date
Mar 2, 2020
52 Week Low
4.26
52 Week Low Date
May 13, 2019
52 Week Price Change
12.44
52 Week Gain
220.18%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 27. 2017
10.83
Apr 7. 2017
11.64
9 Trading Days
7.47%
Link
LONG
Aug 22. 2017
8.66
Sep 13. 2017
10.10
15 Trading Days
16.64%
Link
LONG
Jan 22. 2018
10.27
Feb 5. 2018
11.26
10 Trading Days
9.62%
Link
LONG
Feb 12. 2018
13.20
Mar 15. 2018
16.03
22 Trading Days
21.41%
Link
LONG
May 2. 2018
15.52
May 24. 2018
18.03
16 Trading Days
16.17%
Link
LONG
Aug 28. 2018
18.34
Sep 6. 2018
19.29
6 Trading Days
5.18%
Link
LONG
May 20. 2019
5.14
May 31. 2019
5.65
8 Trading Days
9.88%
Link
LONG
Jul 2. 2019
6.54
Aug 2. 2019
8.36
22 Trading Days
27.87%
Link
LONG
Sep 5. 2019
9.45
Sep 20. 2019
10.63
11 Trading Days
12.48%
Link
LONG
Oct 25. 2019
11.19
Dec 6. 2019
16.59
29 Trading Days
48.25%
Link
LONG
Dec 16. 2019
16.99
Jan 2. 2020
18.26
11 Trading Days
7.50%
Link
LONG
Feb 28. 2020
16.34
Mar 9. 2020
21.41
6 Trading Days
31.04%
Link
Company Information
Stock Symbol
KPTI
Exchange
NasdaqGS
Company URL
http://www.karyopharm.com
Company Phone
617-658-0600
CEO
Michael G. Kauffman
Headquarters
Massachusetts
Business Address
85 WELLS AVENUE, SECOND FLOOR, NEWTON, MA 02459
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001503802
About

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Its selective inhibitors of nuclear export compounds function by preventing the export of tumor suppressor proteins from the nucleus of a cell. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Description

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.